Table 2.
Univariate and multivariate analysis by Cox proportional hazards models in SEER and METABRIC cohorts.
| Cohort 1: SEER BCSS | Cohort 2: METABRIC BCSS | |||||
|---|---|---|---|---|---|---|
| Univariate | Univariate | |||||
| HR | 95% CI | P | HR | 95% CI | P | |
| ER+PR+HER2- | 1 | - | - | 1 | - | - |
| ER+PR-HER2- | 3.67 | 3.31-4.06 | <0.001 | 1.70 | 1.26-2.30 | 0.001 |
| ER-PR-HER2- | 7.58 | 7.06-8.15 | <0.001 | 2.41 | 1.78-3.27 | <0.001 |
| Multivariatea | Multivariateb | |||||
| HR | 95% CI | P | HR | 95% CI | P | |
| ER+PR+HER2- | 1 | - | - | 1 | - | - |
| ER+PR-HER2- | 2.85 | 2.58-3.14 | <0.001 | 1.54 | 1.14-2.09 | 0.005 |
| TNBC | 5.43 | 5.03-5.86 | <0.001 | 2.02 | 1.43-2.84 | <0.001 |
BCSS: breast cancer-specific survival; CI: confidence intervals; ER: estrogen receptor; HR: hazard ratio; HER2: human epidermal growth factor receptor 2; METABRIC: Molecular Taxonomy of Breast Cancer International Consortium; PR: progesterone receptor; SEER: Surveillance, Epidemiology, and End Results; TNBC: triple negative breast cancer.
a Adjusted by Cox proportional hazards models including age, race, stage, grade, histology, chemotherapy, and surgery.
b Adjusted by Cox proportional hazards models including age, grade, stage, chemotherapy and surgery.